Drug Trial Radar · NCT06183216
A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine
Last checked: Nov 19, 2026Latest source record: Jan 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
140
Actual
Start
Jan 4, 2024
Primary completion
Mar 26, 2025
Study completion Mar 26, 2025
Sponsor
- Lead sponsor
- Sinovac Research and Development Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 weeks, up to 5 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A phase 1b clinical trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) developed by Sinovac Life Science Co., Ltd will be conducted in children aged 2 months (42-89 days) and 2 to 5 years. The objective of the study is to evaluate the safety and immunogenicity of Sinovac PCV13. The trial is a randomized, double blinded, positive controlled study.
Conditions
- Pneumococcal Infectious Disease
Interventions
Sinovac PCV13Biological
0.5 mL dose of Sinovac PCV13 contains 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F saccharides.
PREVNAR 13Biological
0.5 mL dose of PREVNAR 13 contains 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F saccharides.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse reactionsTime frame: 0-30 days after each dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Binchuan County Center for Diseases Control and Prevention
Dali, Yunnan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.